We work with medical oncologists/hematologists across the country in both the private practice and hospital settings. Based on our experience, I'd like to point out a couple of key flaws in the current Medicare code interpretations.
There are two fundamentally different ways of thinking about complex social systems: the economic approach and the engineering approach.
Despite efforts by the manufacturer to reduce the cost of Avastin, the clinical effectiveness agency for England and Wales says that it will not recommend the drug for the first-line treatment of metastatic colorectal cancer.
On August 18th during a meeting with “The Pink Sheet Daily” Biotechnology Industry Organization CEO Jim Greenwood said, CMS decision to conduct Provenge NCA could be “Chilling to future innovation.”
Is the healthcare debate stressing you out? Check out this raft of political cartoons courtesy of Kaiser Health News.
As adoption of electronic health records (EHRs) continues to grow, there still exists a gap in the ability of some providers and vendors to ensure successful implementation. This starter-kit of resources can help you take advantage of government incentives and prepare you for EHR adoption.
Almost everyone says that it is. Conservatives. Liberals. Republicans. Democrats. A vast swath of the health policy community. With near unanimous agreement among everybody who knows anything about health economics, how could we even ask the question?
Looking to expand the reach of its care beyond the hospital’s walls and hours of operation, Roswell Park Cancer Institute (RPCI) has launched a new online community for people affected by cancer.
According to ONCOLOGY contributor, Debu Tripathy, MD, FDA's process for the final approval of Avastin for advanced breast cancer raises many questions about the standards on drug approval in this changing era of targeted therapy and personalized medicine.
The passage of MMA changed the oncology practice landscape, now we’re entering into unknown territory with Obama’s reform bill. Voice your opinions/perspectives on practice and policy issues affecting cancer care with 35,000 of your colleagues on the pages of ONCOLOGY.